The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors - PubMed (original) (raw)

Review

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

Craig W Lindsley et al. Curr Cancer Drug Targets. 2008 Feb.

Abstract

This article describes recent advances in the development and biological evaluation of allosteric and ATP-competitive small molecule inhibitors for the serine/threonine kinase Akt (protein kinase B, PKB). Unregulated activation of the PI3K/Akt/PTEN pathway is a prominent feature of many human cancers and Akt is over-expressed or activated in all major cancers making Akt an exciting new target for cancer therapy. The development of Akt inhibitors has been complicated and hampered by the presence of three Akt isozymes, (Akt1, Akt2 and Akt3) which differ in function and tissue distribution, as well as a lack of Akt specific inhibitors. In the past 18 months, a large number of reports have appeared describing the discovery and development of allosteric Akt kinase inhibitors and classical ATP-competitive Akt kinase inhibitors. This review will discuss the PI3K/Akt/PTEN pathway, allosteric and ATP-competitive Akt kinase inhibitors, their biological evaluation and progress towards target validation.

PubMed Disclaimer

Cited by

The requirement of the mitochondrial protein NDUFS8 for angiogenesis.
Xiong QW, Jiang K, Shen XW, Ma ZR, Yan XM, Xia H, Cao X. Xiong QW, et al. Cell Death Dis. 2024 Apr 9;15(4):253. doi: 10.1038/s41419-024-06636-3. Cell Death Dis. 2024. PMID: 38594244 Free PMC article.
A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
Zhang L, Shi X, Zhang L, Mi Y, Zuo L, Gao S. Zhang L, et al. Cell Death Dis. 2024 Mar 11;15(3):204. doi: 10.1038/s41419-024-06585-x. Cell Death Dis. 2024. PMID: 38467612 Free PMC article.
Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Djuzenova CS, Fiedler V, Memmel S, Katzer A, Sisario D, Brosch PK, Göhrung A, Frister S, Zimmermann H, Flentje M, Sukhorukov VL. Djuzenova CS, et al. BMC Cancer. 2019 Apr 3;19(1):299. doi: 10.1186/s12885-019-5517-4. BMC Cancer. 2019. PMID: 30943918 Free PMC article.
Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.
Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, Kester MGD, Falkenburg JHF, Schaap NPM, Jansen JH, Gattinoni L, Dolstra H, van der Waart AB. Mousset CM, et al. Oncoimmunology. 2018 Aug 6;7(10):e1488565. doi: 10.1080/2162402X.2018.1488565. eCollection 2018. Oncoimmunology. 2018. PMID: 30288356 Free PMC article.
Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels.
Starkus JG, Poerzgen P, Layugan K, Kawabata KG, Goto JI, Suzuki S, Myers G, Kelly M, Penner R, Fleig A, Horgen FD. Starkus JG, et al. J Nat Prod. 2017 Oct 27;80(10):2741-2750. doi: 10.1021/acs.jnatprod.7b00515. Epub 2017 Oct 11. J Nat Prod. 2017. PMID: 29019677 Free PMC article.

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors - PubMed (original) (raw)